Table 2.

Genes associated with GBM patient TTP

Accession no.GeneDescriptionHazard ratio*P
Capecitabine metabolism genes
    NM_001033RRM1Ribonucleotide reductase M12.300.002
    NM_000110DPYDDihydropyrimidine dehydrogenase1.230.002
    NM_012474UCK2Uridine-cytidine kinase 22.140.004
    NM_001905CTPSCTP synthase19.630.009
    NM_004955SLC29A1Solute carrier family 29, member 11.060.010
    NM_001953TPThymidine phosphorylase (ECGF1)1.110.010
    NM_001785CDACytidine deaminase1.660.020
Radiation response genes
    NM_002875RAD51RAD51 homolog1.060.007
    NM_002524NRASNeuroblastoma RAS1.490.007
    NM_005432XRCC3XRCC36.050.008
    NM_012415RAD54BRAD54 homolog B1.210.009
    NM_005732RAD50RAD50 homolog1.620.009
    NM_003401XRCC4XRCC41.280.010
    NM_001641APEX1APEX nuclease 12.200.012
    NM_000124ERCC6ERCC61.900.013
    NM_014481APEX2APEX nuclease 21.740.018
    NM_021141XRCC5XRCC52.480.019
    NM_000251MSH2mutS homolog 237.500.022
    NM_006297XRCC1XRCC11.350.023

NOTE: Cox regression analysis was used to assess the association between TTP and each individual gene expression value, adjusted for age and dose.

  • *Hazard ratio > 1: higher gene expression, shorter time-to-progression; hazard ratio < 1: higher gene expression, longer time-to-progression; hazard ratio = 1: no association.